RA0289

antibody from Oursmab

Targeting: HGF DFNB39, F-TCF, HGFB, HPTA, SF

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0289

Provider

Oursmab

Product name

Ficlatuzumab (Biosimilar Reference Antibody) (HGF)

Antibody type

Monoclonal

Description

Ficlatuzumab (development code AV-299) is an investigational, humanized monoclonal IgG1 antibody developed for the treatment of solid tumors, with a particular focus on squamous cell carcinoma of the head and neck (SCCHN) and non-small cell lung cancer (NSCLC). It functions as a hepatocyte growth factor (HGF) inhibitor. By binding with high affinity to HGF in the tumor microenvironment, ficlatuzumab prevents HGF from interacting with its receptor, c-Met (the mesenchymal-epithelial transition factor), on cancer cells and stromal cells. This blockade inhibits the activation of the HGF/c-Met signaling pathway, which is implicated in tumor growth, angiogenesis, invasion, metastasis, and resistance to other targeted therapies (such as EGFR inhibitors).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Ficlatuzumab (Biosimilar Reference Antibody) (HGF)-RA0289-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Ficlatuzumab (Biosimilar Reference Antibody) (HGF)-RA0289 in a linear range of 3.91-125 ng/mL.